clinical trial · NCT05064488
Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·phase1·completed·n = 40
HealthyEvobrutinib (45mg)Digoxin (0.25mg)Metformin (10mg)Rosuvastatin (10mg)Sumatriptan (25mg)
brief summary
This study consisted of 2 parts: Part 1 and 2. The purpose of this study was to evaluate the pharmacokinetic, safety and tolerability of multiple doses of evobrutinib on single doses of digoxin, metformin and rosuvastatin in Part-1 and sumatriptan in Part-2 of the study.
started
Oct 4, 2021
primary completion
Dec 10, 2021
completion
Dec 10, 2021
last updated
Dec 5, 2025
official title
A Phase I, Open-Label, Two-Part Study of the Effect of Multiple-Dose Evobrutinib on Transporter Substrates Digoxin, Metformin, Rosuvastatin, and Sumatriptan Pharmacokinetics in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol